These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3720033)

  • 1. Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels.
    Brahm M
    Clin Nephrol; 1986 May; 25(5):231-5. PubMed ID: 3720033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accumulation of aluminum in a nondialyzed uremic child receiving aluminum hydroxide.
    Griswold WR; Reznik V; Mendoza SA; Trauner D; Alfrey AC
    Pediatrics; 1983 Jan; 71(1):56-8. PubMed ID: 6848980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.
    Demontis R; Leflon A; Fournier A; Tahiri Y; Herve M; Moriniere P; Abdull-Massih Z; Atik H; Belbrik S; Renaud H
    Clin Nephrol; 1986 Sep; 26(3):146-9. PubMed ID: 3769230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Iatrogenic aluminum osteopathy in a uremic infant].
    Koch H; Reich H; Franke D; Delling G
    Monatsschr Kinderheilkd; 1986 May; 134(5):279-81. PubMed ID: 3724766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aluminum and magnesium burden of dialysis patients using antacids. A comparative study].
    Eichhorn M
    Fortschr Med; 1989 Aug; 107(23):502-6. PubMed ID: 2670719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
    Leung AC; Henderson IS; Halls DJ; Dobbie JW
    Br Med J (Clin Res Ed); 1983 Apr; 286(6375):1379-81. PubMed ID: 6404468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
    Moriniere P; Roussel A; Tahiri Y; de Fremont JF; Maurel G; Jaudon MC; Gueris J; Fournier A
    Proc Eur Dial Transplant Assoc; 1983; 19():784-7. PubMed ID: 6878265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis.
    Oe PL; Lips P; van der Meulen J; de Vries PM; van Bronswijk H; Donker AJ
    Clin Nephrol; 1987 Oct; 28(4):180-5. PubMed ID: 3690899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum.
    Tsou VM; Young RM; Hart MH; Vanderhoof JA
    Pediatrics; 1991 Feb; 87(2):148-51. PubMed ID: 1987526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and treatment of aluminum overload in uremic patients: long-term results.
    Canavese C; Thea A; Pacitti A; Salomone M; Mangiarotti G; Segoloni G; Stratta P; Gurioli L; Constantini S; Giordini R
    Clin Nephrol; 1989 Apr; 31(4):169-74. PubMed ID: 2714022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency].
    Sárszegi Z; Jobst K; Nagy J
    Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)].
    Boukari M; Rottembourg J; Jaudon MC; Clavel JP; Legrain M; Galli A
    Nouv Presse Med; 1978 Jan; 7(2):85-8. PubMed ID: 349501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dialysis encephalopathy syndrome. Possible aluminum intoxication.
    Alfrey AC; LeGendre GR; Kaehny WD
    N Engl J Med; 1976 Jan; 294(4):184-8. PubMed ID: 1244532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of orally administered aluminium hydroxide and results of withdrawal.
    Bournerias F; Monnier N; Reveillaud RJ
    Proc Eur Dial Transplant Assoc; 1983; 20():207-12. PubMed ID: 6657657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.